nivolumab,ipilimumab
bms
['biomarker', 'paradigm', 'marker ']
 i would consider those patients may be managed under dynamic paradigm, using ctdna as potential biomarker to monitor for mrd and recurrence | meets #asco22 #esmo22 
Co-founder @MassiveBio | Director of Oncology Research @capitalhealthnj | Entrepreneur | #genomics #Tech #AI #trials #cancer #startup #unicorn #A17a -My Opinion